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Introduction 
 
Dublin has outperformed even best-case scenarios for COVID-19 mortality among 
homeless and drug using populations. The experience provides important lessons for 
policy discussions on the pandemic, as well as broader lessons about pragmatic 
responses to these key client groups irrespective of COVID-19. The overarching lessons is 
that when government policy is well coordinated and underpinned by a science-driven and 
fundamentally pragmatic approach, lives are saved. Within this, the importance of strategic 
clarity and delivery, housing, lowered thresholds to methadone provision, Benzodiazepine 
(BZD) provision and Naloxone availability were key determinants of policy success. Further, 
given the rapid collapse in policy barriers to these interventions that COVID-19 produced, it 
is important to secure and protect these improved policy responses into the post-COVID-
19 era. 
 
When the COVID-19 pandemic reached Dublin, homeless people were identified as a 
particularly vulnerable group due to their morbidity profile, living conditions and drug use 
behaviour. A key element of the health services’ strategy to protect homeless people from 
COVID-19 involved the expansion of harm reduction practices that resulted in improved 
access to methadone treatment; improved access to Naloxone; shifting the management 
of high dose BZD dependency towards maintenance therapy; and the home delivery of 
prescription drugs (like methadone and BZDs). Prior to COVID-19 all of these policy choices 
were limited by regulatory obstacles and uncertain political will. The response to the 
COVID-19 pandemic has demonstrated some of the unnecessary obstacles placed ahead 
of potentially lifesaving treatments. Further it has only served to reiterate the value and 
logic of harm reduction-based drug policies. The purpose of this policy briefing is to outline 
and explore those initiatives and to consider the future policy implications. 
 
The Onset of COVID-19 in Ireland 
 
On December 31st, 2019, China alerted the World Health Organisation (WHO) to several 
cases of unusual pneumonia in Wuhan, a port city in the central Hubei province. In February 
2020, the WHO officially named this new Coronavirus ‘COVID-19’ and on 11th March 2020 
the WHO declared the COVID-19 outbreak a pandemic. On 12th March 2020 schools in 
Ireland closed to help reduce the spread of COVID-19. Five days later, on 17th March, 
Taoiseach Leo Varadkar addressed the nation stating that, ‘Never will so many ask so 
much of so few,’ (Bray, 2020) referring to the people on the front line of the response to 
COVID-19 in Ireland. Ten days later, on 27th March, at midnight, further restrictions 
designed to reduce the spread of COVID-19 came into place. 
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Fear and uncertainty permeated the public and professional consciousness. It was also a 
time that demanded action. It was clear that the best should not be allowed to become the 
enemy of the good, and this view – that policy makers must respond quickly and not fear 
taking risks nor making mistakes – drove much of the policy innovation during this time. 
This was the message from the Executive Director of the WHO’s Health Emergencies 
Programme, Dr Michael Ryan, when he said: 
 
…if you need to be right before you move you will never win. Perfection is the enemy 
of the good when it comes to emergency management. Speed trumps perfection 
and the problem in society we have at the moment is everyone is afraid of making 
a mistake, everyone is afraid of the consequence of error. But the greatest error is 
not to move, the greatest error is to be paralysed by the fear of failure…(World Health 
Organisation, 2020) 
 
This crisis elicited a galvanized response amongst the homeless specialised General 
Practitioner (GP) services, the harm reduction services and the Dublin Homelessness 
Executive (DRHE). This was then coordinated by the Social Inclusion and Addiction 
Services of the Health Service Executive (HSE).  The quick overarching coordination helped 
ensure that specific policy responses moved with speed and clarity. We examine some of 
these in turn. 
 
Housing 
 
At the outset of the policy response there was a very clear sense of what client groups were 
being targeted. Namely it focused on people who are homeless (Housing Act, 1988), and 
who use drugs in Dublin city centre, an area with the highest population of these clients 
(Keane et al., 2018). Very early on, the HSE appointed a Clinical Lead for the COVID-19 
Homeless Response. Protocols for identification and immediate testing for homeless 
clients with symptoms were developed and implemented. Accommodation to allow 
isolation of positive and suspected cases was rapidly obtained by the DRHE and staff were 
funded by the HSE. Homeless clients who were deemed vulnerable due to age or medical 
condition were moved to single occupancy accommodation so that they could be shielded 
from infection. In addition, homeless accommodation with large numbers of residents saw 
many transferred in order to decrease occupancy levels and thereby to reduce the risk of 
spreading COVID-19. By early June: 
• over 750 clients had been tested;  
• over 330 clients had been placed in isolation;  
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• over 500 people had been placed in shielding, of whom 340 were shielded in newly 
obtained units;  
• 120 people were moved from high occupancy units to new reduced-occupancy 
accommodation;  
• all rough sleepers were offered accommodation.  
 
The result was that COVID-19 infection and mortality rates were very low with only 63 
homeless people diagnosed. There was only one COVID-19 related death, a fraction of what 
had been predicted (see Figure 1). The expansion of housing provision  was an unequivocal 
success in limiting the direct effects of COVID-19 transmission and infection. Swift, 
decisive action from all sectors, properly coordinated by public servants, was reflected in 
this outcome. Policy and central coordination was not sufficient, it was the enabling 
backdrop that made change possible for many organisations who responded quickly by 
adapting existing services; redeploying staff; opening new services; and who generally took 
significant personal risks upon themselves and their loved ones to support the public 
health response.  When these various factors coalesced, including top level institutional 
and political support, clear coordination coupled with command and control decision 
making capabilities, existing organisational capacity and a willingness and ability to adapt 
this, and the sheer dedication and bravery of front line service workers, decisions that 
would normally take many months or years were effected within days and weeks.  
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Mortality from COVID-19 Homeless Sector
Predicted No Deaths If No Action. Predicted No of Deaths with Action
Actual Total No of Deaths
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Methadone Provision 
 
Correlations between opiate dependence and negative impacts on life expectancy, physical 
and mental health and social functioning are well documented. The impacts of 
stigmatising and repressive policies which undermine public health based approaches 
have a similarly extensive research underpinning (Csete, 2016, 2014).The benefits of 
treatment with Opiate Substitution Therapy (OST) for individual users’ health and wellbeing 
are well recognized. As the WHO states,  
 
Opioid agonist maintenance treatment (OAMT) with long-acting opioids 
(methadone or buprenorphine), which is combined with psychosocial assistance, is 
the most effective pharmacological intervention for opioid dependence (United 
Nations, 2020, p. 61). 
 
Alongside the gains for individual clients, there are also demonstrable spill over gains from 
OST for society in general. These include reduced criminal activity, reduced healthcare 
costs, lower social welfare costs, and improved social functioning (Garcia‐Portilla et al., 
2014). 
 
In Dublin there are two main routes for homeless clients to access OST. First, the National 
Drug Treatment Centre (NDTC), which is a designated OST service for homeless people 
from across Ireland. The NDTC is based in Dublin City Centre and is the largest treatment 
centre in the Republic. Prior to the COVID-19 Crisis the NDTC had circa 550 clients with 
methadone being dispensed on site. Second, GMQ Medical, which was established as a 
primary care service for homeless people based out of the Granby and Merchants Quay 
day services.   
 
Prior to the COVID-19 crisis, GMQ Medical had circa 150 clients.  However, GMQ Medical 
had a cap on numbers of patients/hostels it could recruit and NDTC had capacity issues 
affecting the number of people that they could provide OST to.  Due to the large increase 
in the homeless population in Ireland since the 2007 recession, there has been an 
imbalance between numbers applying for treatment and those actually being transferred 
to the community. This resulted in a waiting time for treatment for GMQ Medical of 
between 12-14 weeks. Delayed treatment admission is associated with numerous risks, 
including higher rates of intravenous drug usage, overdose, blood borne viral infection and 
increased mortality (Csete et al., 2016). Nationally, waiting times are determined by a 
combination of the limits placed on client numbers by clinics, the availability of prescribing 
doctors and the number of community pharmacy places available. If places are unavailable 
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clients are placed on a national waiting list (Health Service Executive, n.d.). Long waiting 
times for homeless people accessing OST are, of course, not unique to Dublin.  
 
It was quickly recognised that one of the main deterrents to individual compliance with 
isolation and shielding guidelines was substance use. A large number of patients presented 
who were heroin dependent and were not availing of OST.  Immediately, the HSE issued 
national contingency guidelines allowing for reduced waiting times and removal of caps on 
recruitment to treatment (Health Service Executive, 2020). In addition, other Drug 
Treatment Clinics agreed to take on homeless patients resident in hostels in their 
catchment areas. Waiting times dropped overnight from 12-14 weeks to 2-3 days. An 
inpatient unit for rapid initiation on to OST for COVID-19 positive, and suspected, patients 
was established. This four-bedded unit was set up in one of the new homeless Isolation 
Units where it had access to 24-hour nursing care.  
 
In addition, it was recognized that clients both in isolation and shielding facilities, would be 
exposed to risk if they had to collect their OST and medication at treatment centres or 
pharmacies. The EMCDDA had already highlighted that “access to medication is likely to 
be particularly challenging for those self-isolating, under lock down or in quarantine” 
(EMCDDA, 2020). Supervision guidelines were amended to allow members of the NDTC 
and two non-governmental organisation (NGO) Harm Reduction services, Ana Liffey Drug 
Project and Chrysalis Community Drug Team, to collect clients’ OST and other medication 
and deliver it at intervals dictated by the client’s risk of overdose. 
 
Thus, the crisis demonstrated that whatever systemic factors had heretofore maintained 
long waiting times for OST, the COVID-19 impetus saw them removed overnight. Despite 
an initial EMCDDA warning that due to the COVID-19 pandemic there was, “a risk of reduced 
access to opioid substitution therapy and other essential medications” (EMCDDA, 2020) 
waiting times for methadone actually reduced. Overall an extra 160 clients were initiated 
on treatment by GMQ Medical and 44 by NDTC. Of those started by GMQ Medical, 57 had 
been sleeping rough prior to initiation of treatment. This was an unequivocal policy success 
and one from which broader drug policy lessons in Ireland and indeed around the world 
can be drawn. 
 
BZD Maintenance 
 
There is an increasing problem with high dose BZD dependence both internationally and in 
Dublin (Darker et al., 2012; Yamamoto et al., 2019). Up to 66% of patients on OST misuse 
BZDs (Nielsen et al., 2007). In Dublin, 62% of homeless people on OST also misuse street 
BZDs. BZDs have been implicated in up to 60% internationally, and in Ireland in 92% and 
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81% of overdose deaths respectively where methadone or heroin were implicated (Dhalla 
et al., 2009; Health Research Board, 2017).  In Dublin, there is a national guideline for BZD 
detoxification but none for maintenance treatment (Progression Routes Iniative, 2011). 
Existing guidelines on BZDs recommend detoxification (Health Service Executive, n.d.). 
Patients on OST get offered either a BZD detox or a maintenance course usually depending 
on individual clinician preference.  This is consistent with international practice, where 
there is no consensus on the most appropriate clinical intervention (Baandrup et al., 2015; 
Liebrenz et al., 2010; Soyka, 2010; Tyrer, 2010). The majority of guidelines examined favour 
gradual detoxification followed by complete abstinence irrespective of the duration and 
severity of misuse (Lader et al., 2009; Parr et al., 2009). However, in practice, clinicians 
working in addiction services that have no formal protocol for BZD maintenance often still 
end up prescribing long term BZDs (Tjagvad et al., 2016). 
 
Prior to the COVID-19 pandemic, GMQ Medical offered BZD detoxes based on the national 
protocol, but only offered BZD maintenance in occasional cases where previous detoxes 
had failed and the client was seen to be at high risk from substance misuse. This approach 
was influenced by the presence of a clear national policy for BZD detox and an absence of 
a similar policy for BZD maintenance. As COVID-19 infections started to rise in Dublin and 
clients were placed in Isolation Units and Shielding Units, it was realised that those with 
high dose BZD dependence were unlikely to remain in their accommodation so increasing 
their, and other residents’, risk of infection. National contingency guidelines emerged 
recommending that patients in isolation could be offered up to 30mg daily to prevent 
withdrawals for the period of isolation only. In the homeless sector over 70 people were 
commenced on BZD maintenance treatment. The homeless sector decided to offer 
maintenance treatment to patients either in Isolation or Shielding. These medications were 
collected daily by Ana Liffey Drug Project and Chrysalis Community Drug Teams and 
delivered to the clients in their accommodation.  
 
The homeless health sector met weekly. It was reported at these meetings that the health 
and behaviour of clients on maintenance had seemed to improve and that they had 
complied with the isolation/shielding recommendations. As a result, GMQ Medical 
reviewed their policy on BZDs and decided to offer BZD maintenance treatment to all 
patients on OST with established BZD dependency. Dependency was established by 
interviewing the patient, reviewing their urine results and any history of failed BZD detoxes.  
A number of clinicians have advocated for maintenance (agonist substitution) treatment 
for those who have difficulties detoxing or abstaining from BZD misuse (Liebrenz et al., 
2010; Wickes et al., 2000). There is evidence supporting the efficacy of this approach 
(Lingford-Hughes et al., 2004). Weizman et al. found that 79% of patients placed on a 
maintenance of Clonazepam remained abstinent for at least one year (Weizman et al., 
2003). Bakker et al. had been offering BZD maintenance to clients in a GP run methadone 
clinic in London since 1994. They found those on maintenance had higher treatment 
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retention and lower mortality than patients who had never been or occasionally been 
prescribed BZDs (Bakker and Streel, 2017). Eibl et al. found that patients who were not 
prescribed BZDs as part of routine treatment were twice as likely to leave treatment 
compared to those on maintenance (Eibl JK et al., 2019). Thus, given this extensive 
evidence base, GMQ Medical, as a result of the COVID-19 crisis, shifted practice-based 
policy towards the use of BZD maintenance where clients demonstrated dependency on 
BZD and wished to have a maintenance treatment.  
 
Naloxone 
 
Naloxone is an opioid antagonist recommended by the WHO for the treatment of opioid 
overdose (World Health Organisation, 2014).  Naloxone is used for the complete or partial 
reversal of opioid overdose, including respiratory depression.  There is a wide body of 
evidence demonstrating its efficacy (EMCDDA, n.d.). Depending upon the jurisdiction, 
access to Naloxone varies.  Take for example the UK, Ireland’s closest English speaking 
neighbour. In 2005 in the UK, Naloxone was introduced as a medication to be administered, 
by injection, by anyone for the purpose of saving a life. However, it was classed as a 
Prescription Only Medicine and was not initially available over the counter but was supplied 
using a Patient Group Direction (PGD) or in some cases a prescription.  In October 2015, 
there was a regulatory change and it is now much more widely available and accessible 
without the need for a PGD or prescription (Kirsten Horsburgh, 2018). 
 
In Ireland there are relatively more restrictive pathways for accessing Naloxone (Clarke and 
Eustace, 2016). This requires a trained keyworker to initially conduct a risk assessment and 
to educate the client about Naloxone and train them, or their relatives, on how to administer 
either or both the nasal and injectable forms of Naloxone. Once this is completed the client 
requires a doctor (usually their own GP, a GP working in specialised homeless services or 
an OST addiction prescriber) to issue a prescription for the Naloxone. Due to the scheduling 
of Naloxone in Ireland the person to whom it is prescribed must not give the Naloxone to 
anyone else to hold for them. However, the HSE did allow for GPs to issue prescriptions 
retrospectively within a 24 hour period to allow, in particular, for the administration of 
Naloxone in an overdose scenario (Author’s Private Communication, HSE). 
 
With time, it emerged that staff working in homeless services were encountering people 
who had overdosed, but to whom Naloxone had not been prescribed. It was decided that 
in these situations, homeless emergency accommodation providers could administer 
Naloxone as long as the name and date of birth of the person to whom Naloxone was 
administered was sent to a GP within 72 hours. The GP would then issue a prescription. It 
was felt that this sufficiently adhered to the regulatory requirements under controlled drug 
scheduling.   
 
On 26th March, 2020, National contingency guidelines were published, by the HSE, for 
anyone who was working with people who use drugs (PWUD). It recognised the urgency of 
the situation and included guidance on Naloxone, recommending that every individual in 
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receipt of OST and in contact with treatment providers should be offered and encouraged 
to take a supply of Naloxone. Further it explained that Naloxone was to be administered by 
a person trained in using the product; and that in the current crisis, injectable Naloxone was 
to be used. The intranasal product was to be avoided and if using the intranasal product, 
precautions were to be taken (Health Service Executive, 2020). 
 
Recognising the increased risk of overdose during the COVID-19 crisis the process was 
quickly adapted to expand access to Naloxone to those most at risk (Health Service 
Executive, 2020). Naloxone packs were taken out by Ana Liffey Drug Project when 
delivering their Needle and Syringe Programme (NSP).  A person engaging with the 
outreach NSP was assessed by Ana Liffey Drug Project; who briefed them and/or their 
partner/companion on the process of using Naloxone and gave them the Naloxone. The 
names and date of birth were later provided to a GP who issued the prescription for 
Naloxone retrospectively. 
 
Conclusion 
 
This policy briefing highlights three changes to practice during the COVID-19 crisis . Two 
of those changes (the removal of barriers to rapid access to methadone and the expanded 
distribution of Naloxone) were such that they resulted in the removal of barriers to the 
implementation of national policy. The question remains as to why the barriers existed prior 
to the crisis. The epidemic created an overwhelming public health argument for the 
facilitation of immediate access to OST and Naloxone. However, a strong public health 
argument for having no waiting lists for OST and improved Naloxone distribution to PWUD 
existed prior to and independent of COVID-19.  
 
It is noteworthy that in the field of Irish medicine the COVID-19 crisis facilitated a number 
of practice changes that had persuasive arguments in their favour prior to COVID-19 e.g. 
emailed prescriptions, electronic social welfare certificates, teleconsultations etc. Why it 
took a pandemic to overcome barriers to seemingly obvious practice reforms is difficult to 
discern. Possibilities include the effect of the fear and uncertainty that was palpable as 
COVID-19 infection spread across the nation; the unification of the health service with a 
clear single mission i.e. to reduce the transmission of infection; or more controversially, the 
fact that the public health arguments in favour of harm reduction related mainly to the 
protection of PWUD whereas the public health arguments that arose during the COVID-19 
crisis related to protecting the public at large.  
 
Meanwhile, the shift of some services to using BZD maintenance resulted from the 
gathering of observations from field workers combined with a review of the evidence 
concerning BZD maintenance. This has resulted in a change in practice that requires 
ongoing evaluation.  
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In summary, the COVID-19 crisis acted as a catalyst for changes in the delivery of harm 
reduction measures to homeless PWUD. Some of these changes enabled the full 
implementation of national policy objectives in relation to OST and Naloxone interventions 
and the expansion of BZD maintenance treatment for patients with high dose BZD 
dependency. We recommend that practices continue to deliver on OST and Naloxone 
policy objectives and that policy makers review the evidence on BZD maintenance 
treatment. We further encourage international jurisdictions to examine the case study 
highlighted here to see if there are any lessons relevant for their immediate efforts to 
reduce COVID-19 transmission and save lives. Longer-term, we view the COVID-19 
experience as a potentially important milestone in the development of national drug 
policies. 
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